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CASE REPORT
Diffuse Cutaneous Mastocytosis with Generalized Bullae
Eui Hyung Lee, M.D., Mi Ri Kim, M.D., Tae Won Kang, M.D., Soo-Chan Kim, M.D., Ph.D.
Department of Dermatology and the Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
We report on a 9-month-old female infant with multiple 
tense bullae and erosions covering the entire body, including 
the face, scalp, and trunk. The histopathological exami-
nation revealed sub-epidermal bullae with a dense dermal 
cellular infiltrate. The infiltrate was identified as a collection 
of mast cells using toluidine blue and Giemsa stains. The 
direct immunofluorscence was negative. A diagnosis of 
cutaneous diffuse mastocytosis with generalized bullae was 
made based on these clinical and histopathological findings. 
In cases with diffuse cutaneous mastocytosis with gene-
ralized bullae, systemic involvement is more frequent and 
more severe compared to other types of cutaneous 
mastocytosis. Some lethal outcomes have been reported. 
This is the first reported case of diffuse cutaneous masto-
cytosis in the Korean literature. (Ann Dermatol 22(1) 77∼80, 
2010)
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INTRODUCTION
Mastocytosis is a rare disease characterized by a primary 
pathological increase in the number of mast cells. It may 
present with a variety of clinical signs and symptoms and 
the prognosis varies. The skin is the most commonly 
involved organ in all types of mastocytosis. Cutaneous 
mastocytosis (CM) is a heterogeneous disorder that is 
divided into three major variants: urticaria pigmentosa 
(UP), diffuse cutaneous mastocytosis (DCM), and masto-
cytoma1-3. Bullous eruption is most commonly associated 
with DCM, although bullae can occur in all forms of CM. 
It is important to differentiate DCM from other bullous 
skin disorders observed in infants, such as epidermolysis 
bullosa, bullous congenital ichthyosiform erythroderma, 
and staphylococcal scalded skin syndrome. Here, we 
report a case of DCM presenting with generalized bullae.
CASE REPORT
A 9-month-old female infant presented with generalized 
blisters that were first noted when she was three months 
old. The lesions were first observed on the hands and feet, 
and spread to the scalp, face, and trunk. The father 
reported a history of blisters on his body when he was a 
child, but he was never evaluated for the problem.
Physical examination revealed multiple, tense vesicles, 
bullae, erosions, and hemorrhagic crusted lesions over the 
face, scalp, and trunk (Fig. 1A, B). The Darier's sign was 
present on the thigh (Fig. 1C). There was no evidence of 
organomegaly or lymphadenopathy. A complete blood 
cell count and the biochemical profiles were within 
normal limits. The histological examination of a biopsy 
taken from the back revealed a sub-epidermal bulla with a 
dense infiltration of mast cells and some eosinophils in the 
upper dermis (Fig. 2). The toluidine blue and Giemsa 
stains showed that almost all of the infiltrating cells in the 
dermis were mast cells (Fig. 3). The direct immunofluor-
scence was negative. The diagnosis of DCM was made 
based on these clinical and histopathological findings. The 
patient was treated with oral levocetrizine HCl, ketotifen 
fumarate, and topical 0.25% prednicarbate ointment. 
Improvement of the symptoms was noted during a 
follow-up examination. Although we recommended 
evaluation for systemic organ involvement, the patient 
was transferred to another hospital based on the request of 
the family.
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Fig. 1. (A, B) Multiple tense bullae 
and erosions developed with peau 
d'orange-like skin on the face, scalp, 
and trunk. (C) Darier's sign was 
positive on the thigh.
Fig. 2. (A) Sub-epidermal bullae with a dense cellular infiltration in the upper dermis (H&E, ×200) and (B) dense mast cell infiltration
with some eosinophils in the upper dermis (H&E, ×400).
DISCUSSION
Cutaneous mastocytosis (CM) is characterized by the 
accumulation of mast cells in the skin without any 
evidence of extra-cutaneous organ involvement. CM is 
associated with both local and systemic symptoms that are 
caused by the excessive production of mast cell-depen-
dent mediators such as histamine, leukotrienes, proteases, 
and/or heparin. The symptoms often vary and can include 
cutaneous flushing, blistering, pruritus, dyspnea, syncope, 
bone pain, and gastrointestinal upset including epigastric 
pain, vomiting, and diarrhea3,4.
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Fig. 3. Mast cells were stained with toluidine blue (A: ×200) and Giemsa stains (B: ×200).
CM is divided into three major subtypes: urticaria 
pigmentosa (UP), mastocytoma, and diffuse cutaneous 
mastocytosis (DCM). Approximately 58∼90% of patients 
with CM have the UP subtype, while 10∼40% of affected 
patients have mastocytoma5-7. DCM is the rarest subtype, 
accounting for only 1.74% of all cases of CM5. UP 
presents as yellow-tan to reddish-brown macules or 
slightly raised papules that are scattered over the trunk 
and extremities. A solitary mastocytoma presents as a 
brown nodule and subsequent skin lesions rarely develop. 
DCM may present as a diffuse reddish-brown discolo-
ration and have a peau d’orange appearance on the entire 
surface of the skin. The development of systemic 
mastocytosis (SM) is thought to be associated with a 
growth factor receptor c-kit mutation and abnormal 
expression of cell surface adhesion antigens. However, no 
clear pathological mechanism has been presented that 
explains the development of CM8-10. Bullous eruption can 
be associated with all three subtypes of CM. In patients 
with UP, the bullous eruption usually develop during 
infancy and may be the presenting symptom11,12. In 
patients with a mastocytoma, the bulla can develop on the 
skin overlying the mastocytoma13. In patients with DCM, 
bullous eruptions are very common during the early stages 
of life, as seen in our patient. The blisters present in a 
variety of sizes and initially contain clear fluid that may 
become hemorrhagic with time. Bullous lesions may 
occur in linear or grouped fashion and often develop on 
the trunk, scalp, and extremities14. These lesions typically 
resolve by 3 to 5 years of age without scarring. The 
blisters seen in a patient with mastocytosis are believed to 
be caused by serine proteases that are released from mast 
cells3.
CM typically presents as a self-limiting disease, particularly 
in children. In about 50% of pediatric patients, the 
symptoms spontaneously resolve by adolescence6. Gene-
rally, DCM is seen initially almost exclusively in infants, 
although it may persist into adult life and has been 
associated with indolent systemic mastocytosis15. DCM 
associated with generalized bullae has a relatively poor 
prognosis, as this presentation has a higher rate of 
transformation to SM, which could cause hepatomegaly, 
splenomegaly, lymphadenopathy, large bone osteolysis, 
and anemia or pancytopenia due to bone marrow 
involvement6,12-14,16. DiBacco and DeLeo17 reported on 
eight infants that manifested bullae as their initial 
symptom of DCM. All of these infants exhibited systemic 
involvement, and two died of their disease. DCM with 
generalized bullae should be differentiated from other 
bullous diseases of childhood such as epidermolysis 
bullosa, staphylococcal scalded skin syndrome, inconti-
nentia pigmenti, epidermolytic hyperkeratosis, acroderma-
titis enteropathica, erythema multiforme, and toxic 
epidermal necrolysis.
The diagnosis of CM is based on the clinical features of 
the patient and the results of the histopathology. The 
symptoms that are caused by the release of mast cell 
mediators and the typical cutaneous lesions are clinically 
suggestive of CM. Darier's sign, the development of a 
wheal and erythema occurring after the brisk stroking of a 
lesion is also a typical finding. Abnormal proliferation of 
dermal mast cells on the skin biopsy specimen confirms 
the diagnosis. The appropriate stains used to detect mast 
cells in tissues include Giemsa, toluidine blue, Leder, and 
monoclonal antibodies that recognize tryptase or CD1174.
The goal of treatment is alleviation of the symptoms and 
prevention of the use of potential mast cell degranulating 
agents or stimuli such as ingested alcohol, anticholinergic 
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preparations, aspirin and other NSAIDs, narcotics, poly-
myxin B sulfate, systemic anesthetics, heat, and friction. 
Anti-mediator drugs such as antihistamines, cromolyn 
sodium, acetyl salicylic acid, and ketotifen are used in 
step-wise fashion to alleviate symptoms1. Cutaneous 
lesions may show good response to the application of 
psoralen plus UVA, local corticosteroids with occlusion, 
or intralesional injections18. Patient with extensive bullae 
may be at increased risk for infection. Therefore, appro-
priate management for preventing cutaneous infections is 
needed. Patients with CM, especially childhood-onset, 
generally have a favorable prognosis. Annual check-ups 
are usually sufficient for long-term management19. How-
ever, DCM with generalized bullous eruption, as seen 
with the patient reported here, may have a higher risk for 
systemic involvement and severe symptoms such as 
sudden death. Therefore, proper follow-up with evalua-
tions for systemic involvement is required for these pa-
tients.
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